ASH® 2025 Highlights: Presenter Vignette – Doris Hansen
Doris Hansen
MD
Moffitt Cancer Center
93
Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.